DOP2019000071A - Compuestos de indazol para usar en lesiones de tendones y/o ligamentos - Google Patents
Compuestos de indazol para usar en lesiones de tendones y/o ligamentosInfo
- Publication number
- DOP2019000071A DOP2019000071A DO2019000071A DO2019000071A DOP2019000071A DO P2019000071 A DOP2019000071 A DO P2019000071A DO 2019000071 A DO2019000071 A DO 2019000071A DO 2019000071 A DO2019000071 A DO 2019000071A DO P2019000071 A DOP2019000071 A DO P2019000071A
- Authority
- DO
- Dominican Republic
- Prior art keywords
- ligaments
- tendons
- injury
- compounds
- indazol
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Abstract
La presente invención proporciona un compuesto de fórmula (I) en forma libre o en forma de sal farmacéuticamente aceptable. (I) un método para elaborar los compuestos de la invención, y sus usos terapéuticos. La presente invención además proporciona una combinación de agentes farmacológicamente activos y una composición farmacéutica.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662398869P | 2016-09-23 | 2016-09-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DOP2019000071A true DOP2019000071A (es) | 2019-05-15 |
Family
ID=60084023
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DO2019000071A DOP2019000071A (es) | 2016-09-23 | 2019-03-20 | Compuestos de indazol para usar en lesiones de tendones y/o ligamentos |
Country Status (38)
| Country | Link |
|---|---|
| US (1) | US10112907B2 (es) |
| EP (1) | EP3515894B1 (es) |
| JP (1) | JP7007374B2 (es) |
| KR (1) | KR102490953B1 (es) |
| CN (1) | CN109715608B (es) |
| AR (1) | AR109688A1 (es) |
| AU (1) | AU2017332867B2 (es) |
| BR (1) | BR112019005578A2 (es) |
| CA (1) | CA3033249A1 (es) |
| CL (1) | CL2019000727A1 (es) |
| CO (1) | CO2019002616A2 (es) |
| CR (1) | CR20190145A (es) |
| CU (1) | CU24553B1 (es) |
| CY (1) | CY1124301T1 (es) |
| DK (1) | DK3515894T3 (es) |
| DO (1) | DOP2019000071A (es) |
| EA (1) | EA038510B1 (es) |
| EC (1) | ECSP19019589A (es) |
| ES (1) | ES2878585T3 (es) |
| HR (1) | HRP20211006T1 (es) |
| HU (1) | HUE054910T2 (es) |
| IL (1) | IL265066B (es) |
| JO (1) | JOP20190054B1 (es) |
| LT (1) | LT3515894T (es) |
| MX (1) | MX2019003362A (es) |
| MY (1) | MY196425A (es) |
| PE (1) | PE20190657A1 (es) |
| PH (1) | PH12019500327A1 (es) |
| PL (1) | PL3515894T3 (es) |
| PT (1) | PT3515894T (es) |
| RS (1) | RS62145B1 (es) |
| RU (1) | RU2749547C2 (es) |
| SG (1) | SG11201901146SA (es) |
| SI (1) | SI3515894T1 (es) |
| TW (1) | TWI651308B (es) |
| UY (1) | UY37412A (es) |
| WO (1) | WO2018055550A1 (es) |
| ZA (1) | ZA201900860B (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JOP20190053A1 (ar) * | 2016-09-23 | 2019-03-21 | Novartis Ag | مركبات أزا إندازول للاستخدام في إصابات الأوتار و/ أو الرباط |
| WO2020144604A1 (en) | 2019-01-11 | 2020-07-16 | Novartis Ag | Lta4h inhibitors for the treatment of hidradenitis suppurativa |
| TW202342048A (zh) | 2022-02-28 | 2023-11-01 | 瑞士商諾華公司 | 使用ｌｏｕ０６４治療化膿性汗腺炎之方法 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA006205B1 (ru) * | 2000-11-02 | 2005-10-27 | Уайт | 1-арил- или 1-алкилсульфонилгетероциклилбензазолы в качестве лигандов 5-гидрокситриптамина-6 |
| US7105532B2 (en) | 2000-12-19 | 2006-09-12 | Smithkline Beecham Corporation | Pyrazolo[3,4-c]pyridines as gsk-3 inhibitors |
| WO2004078163A2 (en) | 2003-02-28 | 2004-09-16 | Transform Pharmaceuticals, Inc. | Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen |
| FR2871158A1 (fr) | 2004-06-04 | 2005-12-09 | Aventis Pharma Sa | Indazoles substitues, compositions les contenant, procede de fabrication et utilisation |
| DE102004028862A1 (de) * | 2004-06-15 | 2005-12-29 | Merck Patent Gmbh | 3-Aminoindazole |
| TW200616967A (en) | 2004-06-24 | 2006-06-01 | Smithkline Beecham Corp | Novel indazole carboxamides and their use |
| FR2889526B1 (fr) | 2005-08-04 | 2012-02-17 | Aventis Pharma Sa | 7-aza-indazoles substitues, compositions les contenant, procede de fabrication et utilisation |
| WO2008104473A2 (en) * | 2007-02-28 | 2008-09-04 | F. Hoffmann-La Roche Ag | Pyrazolopyriidine derivatives and their use as kinase inhibitors |
| BRPI0811065A2 (pt) | 2007-06-08 | 2014-12-02 | Abbott Lab | Indazóis 5-heteroaril substituídos como inibidores de quinase |
| WO2010068287A2 (en) | 2008-12-11 | 2010-06-17 | Angion Biomedica Corp. | Small molecule modulators of hepatocyte growth factor (scatter factor) activity |
| EP2789615B1 (en) | 2009-08-11 | 2017-05-03 | Bristol-Myers Squibb Company | Azaindazoles as Btk kinase modulators and use thereof |
| JP2013542960A (ja) | 2010-11-08 | 2013-11-28 | グラクソスミスクライン、インテレクチュアル、プロパティー、ナンバー２、リミテッド | 脂肪酸シンターゼ阻害剤 |
| WO2012113774A1 (en) * | 2011-02-24 | 2012-08-30 | Nerviano Medical Sciences S.R.L. | Thiazolylphenyl-benzenesulfonamido derivatives as kinase inhibitors |
| US20140107151A1 (en) | 2011-05-17 | 2014-04-17 | Principia Biophama Inc. | Tyrosine kinase inhibitors |
| UA112028C2 (uk) * | 2012-12-14 | 2016-07-11 | Пфайзер Лімітед | Похідні імідазопіридазину як модулятори гамка-рецептора |
| TWI629275B (zh) * | 2013-03-13 | 2018-07-11 | 賽諾菲公司 | Ｎ－（４－（氮雜吲唑－６－基）－苯基）－磺醯胺及其作為醫藥之用途 |
-
2017
- 2017-09-21 UY UY0001037412A patent/UY37412A/es unknown
- 2017-09-21 RS RS20210833A patent/RS62145B1/sr unknown
- 2017-09-21 PT PT177844040T patent/PT3515894T/pt unknown
- 2017-09-21 PL PL17784404T patent/PL3515894T3/pl unknown
- 2017-09-21 TW TW106132361A patent/TWI651308B/zh active
- 2017-09-21 CA CA3033249A patent/CA3033249A1/en active Pending
- 2017-09-21 RU RU2019111883A patent/RU2749547C2/ru active
- 2017-09-21 BR BR112019005578A patent/BR112019005578A2/pt active Search and Examination
- 2017-09-21 HU HUE17784404A patent/HUE054910T2/hu unknown
- 2017-09-21 EA EA201990766A patent/EA038510B1/ru not_active IP Right Cessation
- 2017-09-21 ES ES17784404T patent/ES2878585T3/es active Active
- 2017-09-21 LT LTEP17784404.0T patent/LT3515894T/lt unknown
- 2017-09-21 MY MYPI2019000713A patent/MY196425A/en unknown
- 2017-09-21 AR ARP170102603A patent/AR109688A1/es unknown
- 2017-09-21 CR CR20190145A patent/CR20190145A/es unknown
- 2017-09-21 CU CU2019000028A patent/CU24553B1/es unknown
- 2017-09-21 AU AU2017332867A patent/AU2017332867B2/en active Active
- 2017-09-21 SI SI201730834T patent/SI3515894T1/sl unknown
- 2017-09-21 SG SG11201901146SA patent/SG11201901146SA/en unknown
- 2017-09-21 EP EP17784404.0A patent/EP3515894B1/en active Active
- 2017-09-21 DK DK17784404.0T patent/DK3515894T3/da active
- 2017-09-21 MX MX2019003362A patent/MX2019003362A/es unknown
- 2017-09-21 WO PCT/IB2017/055735 patent/WO2018055550A1/en unknown
- 2017-09-21 JO JOP/2019/0054A patent/JOP20190054B1/ar active
- 2017-09-21 KR KR1020197010512A patent/KR102490953B1/ko active IP Right Grant
- 2017-09-21 CN CN201780057662.4A patent/CN109715608B/zh active Active
- 2017-09-21 JP JP2019515633A patent/JP7007374B2/ja active Active
- 2017-09-21 PE PE2019000680A patent/PE20190657A1/es unknown
- 2017-09-21 US US15/711,984 patent/US10112907B2/en active Active
-
2019
- 2019-02-11 ZA ZA2019/00860A patent/ZA201900860B/en unknown
- 2019-02-15 PH PH12019500327A patent/PH12019500327A1/en unknown
- 2019-02-26 IL IL265066A patent/IL265066B/en active IP Right Grant
- 2019-03-20 CL CL2019000727A patent/CL2019000727A1/es unknown
- 2019-03-20 DO DO2019000071A patent/DOP2019000071A/es unknown
- 2019-03-20 EC ECSENADI201919589A patent/ECSP19019589A/es unknown
- 2019-03-21 CO CONC2019/0002616A patent/CO2019002616A2/es unknown
-
2021
- 2021-06-24 HR HRP20211006TT patent/HRP20211006T1/hr unknown
- 2021-07-05 CY CY20211100601T patent/CY1124301T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP19019613A (es) | Compuestos de azaindazol para usar en lesiones de tendones y/o ligamentos | |
| CR20150628A (es) | Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades | |
| UY35273A (es) | Tiadiazol, análogos del mismo, y métodos para el tratamiento de condiciones relacionadas con defici encia de smn | |
| GT201500030A (es) | Análogos de piridazina 1,4-disustituida y métodos para el tratamiento de condiciones relacionadas con la deficiencia de smn | |
| GT200900283A (es) | "terapia de combinación con un compuesto actuando como un inhibidor del receptor adp plaquetario". | |
| ECSP17007208A (es) | Derivados de indano e indolina y el uso de los mismos como activadores de la guanilato ciclasa soluble | |
| CU24434B1 (es) | Compuestos derivados de n-(1,5-dimetil-3-oxo-2,3-dihidro-1h-pirazol-4-il)-4-metil-5-isoxazol-3-carboxamida activos como inhibidores selectivos de smurf-1 | |
| CL2017000845A1 (es) | Inhibidores de gingipaina de lisina | |
| DOP2019000071A (es) | Compuestos de indazol para usar en lesiones de tendones y/o ligamentos | |
| UY36123A (es) | Derivados de carboxamida | |
| DOP2019000100A (es) | Derivados de naftiridinona y su uso en el tratamiento de la arritmia | |
| CL2019003467A1 (es) | Compuestos bicíclicos 5,6-fusionados y composiciones para el tratamiento de enfermedades parasitarias. | |
| CL2020001277A1 (es) | Derivados de piridinona y su uso como inhibidores selectivos de alk-2. | |
| CU20160170A7 (es) | Derivados de carboxamida | |
| AR105921A1 (es) | Compuestos terapéuticos para el dolor y síntesis de estos |